Biodexa Pharmaceuticals (BDRX) AI Stock Analysis

• Market Cap: $1.10M
• Dividend Yield: N/A
• Average Volume (3M): 260.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.49
• Revenue Growth: -100.00%
• EPS Growth: 86.75%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.00
• Shares Outstanding: 681,789
• 10 Day Avg. Volume: 685,915
• 30 Day Avg. Volume: 260,967
• PEG Ratio: >-0.01
• Price to Book (P/B): 2.41
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.54
• Enterprise Value/Market Cap: -2.49
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 0.56
• Enterprise Value/Ebitda: 0.31
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $2.00 ▼(-14.16% Downside)

The score is pressured primarily by weak financial performance (zero 2024 revenue, persistent losses, and significant ongoing cash burn) and bearish technicals (price well below key moving averages with negative MACD). Valuation does not provide a clear offset due to negative earnings and no dividend yield data.

Positive Factors

Phase 3 Trial Enrollment

The enrollment in a Phase 3 trial for eRapa marks a significant milestone, potentially leading to the first non-surgical treatment for familial adenomatous polyposis, addressing a $7 billion market. This progress could enhance Biodexa's market position and revenue potential.

First Mover Advantage

Being the first mover in developing a non-surgical treatment for FAP provides Biodexa with a competitive edge, potentially capturing significant market share and establishing a leadership position in this therapeutic area.

Grant Funding Support

The $20 million grant from CPRIT supports Biodexa's Phase 3 trial, reducing financial strain and enabling continued R&D efforts. This funding enhances the company's ability to advance its pipeline without immediate reliance on additional equity or debt financing.

Negative Factors

Declining Revenue

The consistent decline in revenue over recent years highlights challenges in product commercialization and market penetration, potentially impacting long-term growth and sustainability if not addressed.

Negative Profit Margins

Negative profit margins suggest inefficiencies in cost management and pricing strategy, which could hinder profitability and limit resources for reinvestment in R&D and market expansion.

Cash Flow Challenges

Persistent negative operating cash flow indicates ongoing cash burn, which may necessitate additional financing to sustain operations, potentially diluting shareholder value or increasing debt burden.

Biodexa Pharmaceuticals Business Overview & Revenue Model

Company Description

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

How the Company Makes Money

Biodexa Pharmaceuticals makes money through the development and commercialization of its pharmaceutical products and drug delivery technologies. The company's revenue model is primarily based on sales of its proprietary drug formulations and delivery systems to healthcare providers, pharmaceutical companies, and distributors. Additionally, Biodexa may engage in strategic partnerships or licensing agreements with other pharmaceutical companies to further develop and market its technologies, which can provide additional revenue streams through milestone payments, royalties, or co-development deals. Key factors contributing to its earnings include successful clinical trials, regulatory approvals, and the ability to effectively market its products to target demographics.

Biodexa Pharmaceuticals Financial Statement Overview

Summary

Financial profile is very weak: revenue declined to zero in 2024, profitability remains deeply negative with negative gross profit and sizable operating losses, and operating/free cash flow are consistently and materially negative with worsening cash burn in 2024. The main offset is low leverage and improved equity versus prior years, providing some balance-sheet flexibility.

Income Statement

The income statement remains very weak: the company is consistently unprofitable with negative gross profit and sizable operating losses across all reported years. Revenue has been small and volatile, and 2024 revenue fell to zero (down 100% year-over-year), worsening operating leverage. While net loss improved significantly versus 2020, profitability is still far from breakeven and margins are structurally pressured.

Balance Sheet

The balance sheet is a relative bright spot: leverage is low (debt-to-equity roughly 0.09 in 2024), which reduces near-term balance-sheet risk. Equity has increased versus 2022–2023, supporting a larger asset base. The key weakness is ongoing negative returns on equity driven by persistent losses, which can erode capital over time if not offset by new funding.

Cash Flow

Cash flow quality is weak, with operating cash flow and free cash flow deeply negative every year, indicating the business is consuming cash rather than generating it. 2024 cash burn widened materially versus 2023, despite the positive free-cash-flow growth figure (which reflects year-to-year movement rather than profitability). A partial positive is that free cash flow tracks net loss closely, suggesting losses are largely cash-based and funding needs are ongoing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	381.00K	699.00K	578.00K	343.00K
Gross Profit	-4.91M	-5.44M	-3.69M	-4.41M	-4.08M	-5.72M
EBITDA	-8.87M	-9.08M	-7.16M	-8.26M	-5.66M	-22.22M
Net Income	-6.23M	-5.73M	-7.08M	-7.66M	-5.46M	-22.19M
Balance Sheet
Total Assets	14.82M	14.78M	10.54M	5.53M	12.91M	9.82M
Cash, Cash Equivalents and Short-Term Investments	4.04M	1.67M	5.97M	2.84M	10.06M	7.55M
Total Debt	501.00K	727.00K	464.00K	624.00K	766.00K	260.00K
Total Liabilities	3.39M	6.46M	5.86M	2.36M	2.46M	3.10M
Stockholders Equity	11.44M	8.32M	4.68M	3.16M	10.45M	6.72M
Cash Flow
Free Cash Flow	-11.53M	-13.04M	-7.09M	-7.11M	-6.33M	-9.51M
Operating Cash Flow	-10.76M	-12.26M	-6.83M	-7.05M	-6.01M	-9.30M
Investing Cash Flow	-183.00K	-598.00K	-265.00K	-220.00K	-278.00K	2.57M
Financing Cash Flow	9.92M	8.56M	10.23M	47.00K	8.80M	3.08M

Biodexa Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.33
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDRX, the sentiment is Negative. The current price of 2.33 is above the 20-day moving average (MA) of 2.22, below the 50-day MA of 3.54, and below the 200-day MA of 7.52, indicating a bearish trend. The MACD of -0.46 indicates Negative momentum. The RSI at 34.91 is Neutral, neither overbought nor oversold. The STOCH value of 15.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BDRX.

Biodexa Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INDP	50 Neutral	$4.93M	-0.07	-317.98%	―	―	34.57%
CNSP	46 Neutral	$3.46M	-0.10	-197.11%	―	―	99.87%
INM	44 Neutral	$3.08M	-0.16	-82.17%	―	-3.27%	51.83%
ENVB	42 Neutral	$4.05M	-0.03	-262.78%	―	―	79.45%
BDRX	41 Neutral	$1.10M	-0.03	-60.37%	―	-100.00%	86.75%

Biodexa Pharmaceuticals Corporate Events

Biodexa Pharmaceuticals Names Fiona Sharp CFO and Board Director

On January 5, 2026, Biodexa Pharmaceuticals PLC appointed long-serving Group Financial Controller Fiona Sharp as its Chief Financial Officer, Corporate Secretary and a member of the Board of Directors, with the move disclosed in a filing dated January 6, 2026. She succeeds Stephen Stamp in the CFO and Corporate Secretary roles, while he remains Chief Executive Officer, and will serve as a director until the company’s 2026 annual general meeting. Sharp, a Chartered Certified Accountant with extensive financial leadership experience in healthcare and communications sectors, has no reported related-party ties or transactions with the company, underscoring a governance-led, continuity-focused leadership transition aimed at reinforcing Biodexa’s financial stewardship and board oversight for stakeholders.

The most recent analyst rating on (BDRX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Biodexa Pharmaceuticals stock, see the BDRX Stock Forecast page.

Biodexa Pharmaceuticals Promotes Fiona Sharp to CFO and Board Director

On January 5, 2026, Biodexa Pharmaceuticals announced the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary and her election to the company’s Board of Directors, effective immediately. Sharp, who joined Biodexa as Group Financial Controller in December 2019, brings extensive senior finance experience from the UK healthcare and communications sectors, including prior roles at Hywel Dda University Health Board and Chime Communications Group. As part of the leadership reshuffle, Stephen Stamp relinquishes his CFO and Company Secretary roles but remains Chief Executive Officer, a move that reinforces Biodexa’s governance structure and clarifies executive responsibilities as the company advances its clinical pipeline.

The most recent analyst rating on (BDRX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Biodexa Pharmaceuticals stock, see the BDRX Stock Forecast page.

Biodexa Pharmaceuticals Prices $10 Million U.S. Public Offering to Fund Pipeline

On December 17–18, 2025, Biodexa Pharmaceuticals PLC launched and priced a best-efforts public offering of American Depositary Share (ADS) units and pre-funded units, structured with accompanying Series L warrants and pre-funded warrants, at combined prices of $3.28 and $3.2799 per unit respectively, for expected gross proceeds of about $10 million and net proceeds of roughly $8.75 million. The offering, conducted under an effective Form F-1 registration statement with Maxim Group LLC as sole placement agent, includes customary purchase and placement agreements, lock-up restrictions on new share issuances and variable-rate financings, and issuance of placement agent warrants, and is expected to close on or about December 19, 2025; Biodexa plans to use the proceeds to fund its development programs, working capital and general corporate purposes, bolstering liquidity after reporting £2.79 million in cash and cash equivalents as of September 30, 2025, although that financial figure is unaudited and subject to change.

The most recent analyst rating on (BDRX) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Biodexa Pharmaceuticals stock, see the BDRX Stock Forecast page.

Biodexa Pharmaceuticals’ Phase 3 Serenta Trial Approved in Europe

On November 3, 2025, Biodexa Pharmaceuticals announced the approval of their Clinical Trial Application by the European Medicines Agency for the Phase 3 Serenta clinical trial of eRapa in patients with familial adenomatous polyposis (FAP). This approval allows the trial to proceed in several European countries, marking a significant step in potentially addressing a $7 billion market for FAP treatment. The trial aims to provide an alternative to the current standard of care, which involves invasive surgeries, by offering a pharmaceutical solution that could improve the quality of life for FAP patients.

The most recent analyst rating on (BDRX) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Biodexa Pharmaceuticals stock, see the BDRX Stock Forecast page.